165 filings
Page 5 of 9
8-K
2meugkf0f i55bqj
20 Mar 20
Entry into a Material Definitive Agreement
4:13pm
8-K
k8c6ysspcykhrefglk
4 Mar 20
Regulation FD Disclosure
4:06pm
8-K
i1k6dupeo3
13 Feb 20
PhaseBio Appoints Alex C. Sapir to Board of Directors
4:07pm
8-K
pmlys5u
11 Feb 20
PhaseBio Announces European Regulatory Update for PB2452
8:08am
8-K
b7ej9fu
4 Feb 20
PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at 14th Pulmonary Vascular Research Institute World Congress
4:08pm
8-K
lod9j efju
13 Jan 20
PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension
4:07pm
8-K
3gyhwm
10 Jan 20
PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452
9:07am
EFFECT
nwds 9eafhbmqycf
9 Jan 20
Notice of effectiveness
12:15am
CORRESP
5wzn4asywcm l8p1zh0
6 Jan 20
Correspondence with SEC
12:00am
UPLOAD
74m0ir b2xdm
3 Jan 20
Letter from SEC
12:00am
S-3
th4ecudr06ty
27 Dec 19
Shelf registration
5:28pm
8-K
wsb uktm6
14 Nov 19
PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress
8:16am
8-K
f9h0bev0
15 Oct 19
PhaseBio Announces First Patient Dosed in Phase 2b Clinical Trial of PB2452 for Reversal of the Antiplatelet Activity of Ticagrelor
8:03am
8-K
ebqzpm 9gj6h1
24 Sep 19
PhaseBio Announces Completion of Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor
4:05pm
8-K
lq66tai7drvc9u6arcrm
14 Aug 19
Regulation FD Disclosure
12:00am
8-K
l4lyd
13 Aug 19
PhaseBio Reports Second Quarter 2019 Financial Results and Recent Corporate Progress
4:05pm
8-K
8opuw7
1 Jul 19
Other Events
8:02am
8-K
7bv2xsxatnlkb
17 Jun 19
Other Events
4:05pm